Lexeo Therapeutics, Inc. Common Stock (LXEO) is a publicly traded Healthcare sector company. As of May 21, 2026, LXEO trades at $5.34 with a market cap of $369.84M and a P/E ratio of -2.67. LXEO moved +14.51% today. Year to date, LXEO is -45.76%; over the trailing twelve months it is +45.04%. Its 52-week range spans $1.45 to $11.72. Analyst consensus is strong buy with an average price target of $18.60. Rallies surfaces LXEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lexeo Unveils Porcine TNNI3 Model and 10L-200L AAV Scale-Up at ASGCT: Lexeo will present seven oral and poster abstracts on its cardiac gene therapy pipeline and optimized Sf9-baculovirus AAV manufacturing platform at the ASGCT Annual Meeting, May 11-15, 2026 in Boston. Key data include porcine TNNI3 cardiomyopathy model results, comparability of HEK293 vs Sf9 suspension AAVrh.10 processes, and 10L-to-200L AAV scale-up.
| Metric | Value |
|---|---|
| Price | $5.34 |
| Market Cap | $369.84M |
| P/E Ratio | -2.67 |
| EPS | $-1.86 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.72 |
| 52-Week Low | $1.45 |
| Volume | 14 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-99.96M |
| Gross Margin | 0.00% |
5 analysts cover LXEO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.60.